Biotech launches with $300 million to expedite RNA drug development; data reveal deeper problems in prisons' Covid response

Taking stock of the drug industry, from the lab to the medicine chest

May 23, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | Biotech launches with $300 million, joint venture to expedite RNA drug development ReNAgade Therapeutics has also started a joint venture with another of MPM's portfolio companies called Orna Therapeutics. By Allison DeAngelis STAT+ | Achieve Life Sciences drug helps smokers quit in trial but would face stiff competition if approved Achieve Life Sciences' smoking cessation drug showed positive results in a Phase 3 trial, but if approved would face competition from varenicline. By Jonathan Wosen 'Worse than what we thought': New data reveals deeper problems with the Bureau of Prisons' Covid response New data reveals that federal prisoners at highest risk for Covid-19 were left waiting months for vaccines and tests. By Nicholas Florko Wilfredo Lee/AP HIV rates decline in U.S., data show, but disparities persist Overall estimated new infections dropped 12% in 2021 compared to 2017, according to new data released Tuesday by the CDC. By Ambar Castillo

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser